Zerion Pharma: A disruptive solution for poor drug solubility

Analyst Comment

CEO Ole Wiborg dived into the potential in the pipeline and where focus will be in the medium to long term. The company decided to change the offering in the private placement.

Watch the video here: https://www.inderes.dk/en/videos/zerion-pharma-a-disruptive-solution-for-poor-drug-solubility.

Zerion Pharma is a non-listed Danish company seeking DKK 5-8 mio. in a private placement round.

Closing date 20. April 2023, Lot size DKK 250.000 and pre-money valuation DKK 70 mio.

Contact: CEO Ole Wiborg - ow@zerion.eu or CFO Jakob Dynnes Hansen - jdh@zerion.eu if you are interested to subscribe and further details.

Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a DigitalIR/Corporate Visibility agreement. Zerion Pharma is a private company (i.e. not listed on a regulated stock market). Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise. /Analyst Claus Thestrup/ANALYST Claus Thestrup 5:30/PM 03-16-2023.